Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
DailyMed / TERLIVAZ exact label
Product / population
TERLIVAZ terlipressin IV injection in adults with hepatorenal syndrome and rapid kidney-function reduction. This is a response-guided HRS regimen, not a stable-CKD CrCl table.
Renal method
SCr, mg/dL and percent response; oxygenation
Source revision
6/2026
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
A response-guided HRS pathway needs eligibility and respiratory review
The official source supplies a complete response pathway absent from the selected RX text rendering. This is not a stable-CKD adjustment table.
What to reconcile: Review oxygenation, volume status, ACLF grade and stopping rules before applying the pathway.
DailyMed / Mallinckrodt Hospital Products Inc. · TERLIVAZ terlipressin IV injection in adults with hepatorenal syndrome and rapid kidney-function reduction. This is a response-guided HRS regimen, not a stable-CKD CrCl table.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Days 1-3: 0.85 mg IV every 6 hours over 2 minutes. On day 4, stop if SCr is at or above baseline; if SCr has fallen by at least 30%, continue 0.85 mg every 6 hours; if it has fallen by less than 30%, the highlights allow increase to 1.7 mg every 6 hours. Continue until 24 hours after two consecutive SCr values <=1.5 mg/dL at least 2 hours apart, or at most 14 days.
Benefit is unlikely above SCr 5 mg/dL. Do not start during hypoxia; monitor continuously and stop if SpO2 falls below 90%. Assess volume status and ACLF grade. This selected pathway does not replace full eligibility, ischemia and respiratory-risk review.
Official Figure 1 visually inspected (turn906730view3); the highlights say the increased dose may be used. Independent clinical adjudication remains pending.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.